1-2 of 2
Kirk Culotta, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Study Of Hyper-CVAD Plus Everolimus In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, MD, Hagop M. Kantarjian, MD, Deborah A. Thomas, MD, Michael E. Rytting, MD, Farhad Ravandi, MD, Nitin Jain, MD, Jorge E. Cortes, MD, Rebecca Garris, BSc, Mary Ann Richie, RN, Marina Konopleva, MD, PhD, Hongbo Hu, PHD, Jitesh Kawedia, PHD, BS, Kirk Culotta Pharmd, BS, Susan O'Brien, MD, Jordan Basnett, Lianchun Xiao, Xuelin Haung, Linda J. Bendall, BSc, PhD
Journal: Blood
Blood (2013) 122 (21): 3916.
https://doi.org/10.1182/blood.V122.21.3916.3916
Published: 2013
Journal Articles

Clofarabine (Clo) and Busulfan (Bu) as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) In Patients (pts) with Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Celina Ledesma, B.S., Kirk Culotta, PharmD, Elizabeth J. Shpall, MD, Stefan O. Ciurea, MD, Amin M Alousi, MD, Marcos De Lima, MD, Uday Popat, MD, Deborah A Thomas, MD, Richard E. Champlin, MD, Borje S Andersson, MD
Journal: Blood
Blood (2010) 116 (21): 3484.
https://doi.org/10.1182/blood.V116.21.3484.3484
Published: 2010